866-997-4948(US-Canada Toll Free)

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 85 Pages

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017

Summary

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) pipeline Target constitutes close to 28 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2017, outlays comprehensive information on the Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Indoleamine-pyrrole 2, 3-dioxygenase 1 is a heme-containing enzyme encoded by the IDO1 gene. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme plays a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 5, 1, 10 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Breast Cancer, Metastatic Melanoma, Pancreatic Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Adenocarcinoma, Alopecia, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Colon Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Lung Cancer, Malignant Glioma, Melanoma, Ocular Melanoma, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
- The report reviews Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics and enlists all their major and minor projects
- The report assesses Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Overview
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Companies Involved in Therapeutics Development
BirchBioMed Inc
Bristol-Myers Squibb Company
Ensemble Therapeutics Corp
F. Hoffmann-La Roche Ltd
Genentech Inc
Globavir Biosciences Inc
Incyte Corp
IO Biotech ApS
Kyowa Hakko Kirin Co Ltd
Netherlands Translational Research Center BV
NewLink Genetics Corp
Pfizer Inc
Redx Pharma Plc
Regen BioPharma Inc
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Drug Profiles
AI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dcellvax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epacadostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-001287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FG-IDO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Galanal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBV-1012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBV-1028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GDC-0919 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IO-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KHK-2455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06840003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70099 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Indoleamine 2,3-Dioxygenase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Oncology and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Lewis Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO-1 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target PDL1 and IDO for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Dormant Products
Indoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Product Development Milestones
Featured News & Press Releases
Jun 05, 2017: Clinical Trial Data for Combination of Epacadostat and Opdivo (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer
Jun 05, 2017: Incyte Analyst and Investor Event to Highlight Clinical Data Presentations from ASCO 2017
Jun 05, 2017: Updated Data from ECHO-202 Trial of Incyte's Epacadostat in Combination with Merck's KEYTRUDA (Pembrolizumab) Demonstrate Clinical Activity across Multiple Tumor Types
Jun 03, 2017: Combination of Incyte's Epacadostat plus Merck's KEYTRUDA (pembrolizumab) Demonstrates Activity in Clinical Trial of Patients with Advanced Non-Small Cell Lung Cancer
May 17, 2017: First Data from Combination of Epacadostat with Opdivo (nivolumab) Will Be Highlighted at ASCO 2017
May 17, 2017: New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda (pembrolizumab)
May 17, 2017: Data from Clinical Study of NewLink Genetics' Navoximod to Be Presented at ASCO 2017
Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO
Apr 20, 2017: Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting
Mar 31, 2017: Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA (pembrolizumab)
Jan 09, 2017: Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA (pembrolizumab)
Sep 28, 2016: Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda (Pembrolizumab)
Sep 28, 2016: iTeos Announces Initiation of Phase 1 Clinical Trial of IDO1 inhibitor
Sep 14, 2016: Regen BioPharma Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
Jul 19, 2016: Updated Data for Epacadostat, Incytes Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by BirchBioMed Inc, H1 2017
Pipeline by Bristol-Myers Squibb Company, H1 2017
Pipeline by Ensemble Therapeutics Corp, H1 2017
Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Pipeline by Genentech Inc, H1 2017
Pipeline by Globavir Biosciences Inc, H1 2017
Pipeline by Incyte Corp, H1 2017
Pipeline by IO Biotech ApS, H1 2017
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Pipeline by Netherlands Translational Research Center BV, H1 2017
Pipeline by NewLink Genetics Corp, H1 2017
Pipeline by Pfizer Inc, H1 2017
Pipeline by Redx Pharma Plc, H1 2017
Pipeline by Regen BioPharma Inc, H1 2017
Dormant Projects, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *